Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H19ClFN4O4.Na.H2O |
Molecular Weight | 558.921 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Na+].COC1=CC(NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C5=C(OC)C=CC=C5F)=CC=C1C([O-])=O
InChI
InChIKey=WLPXWQKMVACWII-UHFFFAOYSA-M
InChI=1S/C27H20ClFN4O4.Na.H2O/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2;;/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33);;1H2/q;+1;/p-1
Molecular Formula | C27H20ClFN4O4 |
Molecular Weight | 518.924 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22016509Curator's Comment: Description was created based on several sources, including
https://www.takeda.com/news/2012/20120306_3946.html
http://adisinsight.springer.com/drugs/800025209
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22016509
Curator's Comment: Description was created based on several sources, including
https://www.takeda.com/news/2012/20120306_3946.html
http://adisinsight.springer.com/drugs/800025209
Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. Alisertib inhibited AAK over ABK with a selectivity of more than 200-fold in cells and produced a dose-dependent decrease in bipolar and aligned chromosomes in the HCT-116 xenograft model, a phenotype consistent with AAK inhibition. Alisertib inhibited proliferation of human tumor cell lines in vitro and produced tumor growth inhibition in solid tumor xenograft models and regressions in in vivo lymphoma models. It is currently in phase II clinical trials for acute myeloid leukaemia; B cell lymphoma; brain cancer; mesothelioma; prostate cancer; small cell lung cancer.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25533335
Curator's Comment: Alisertib (MLN8237) achieved blood-brain barrier penetration
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4722 |
1.2 nM [IC50] | ||
Target ID: CHEMBL1075413 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25074669 |
76.7 nM [IC50] | ||
Target ID: CHEMBL396 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22016509 |
16.0 nM [IC50] | ||
Target ID: CHEMBL390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22016509 |
54.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery and development of aurora kinase inhibitors as anticancer agents. | 2009 May 14 |
|
Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. | 2010 Jun 18 |
|
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. | 2011 Apr 1 |
|
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. | 2015 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01799278
50 mg twice daily for 7 days repeated every 21 days,
administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose, oral dose of Alisertib (MLN8237) should be taken with 8 ounces (1 cup, 240 mL) of water.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20382844
Alisertib (MLN8237) (0.5 uM) treatment inhibits the phosphorylation of Aurora A in human MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. Alisertib (MLN8237) (0.5 uM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:40:32 GMT 2023
by
admin
on
Sat Dec 16 01:40:32 GMT 2023
|
Record UNII |
T76P158V9D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB128442
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
1208255-63-3
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
C142912
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
DBSALT002940
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
T76P158V9D
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
300000024071
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
XX-124
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL483158
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY | |||
|
56843791
Created by
admin on Sat Dec 16 01:40:32 GMT 2023 , Edited by admin on Sat Dec 16 01:40:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |